{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:03:36Z","timestamp":1753877016186,"version":"3.41.2"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100024679","name":"ADVANZ PHARMA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024679","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jemma Lough"},{"name":"Page Medical Communications Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Cystic fibrosis (CF) is an autosomal recessive disorder caused by mutations in the CF transmembrane conductance (CFTR) gene, resulting in the secretion of hyperviscous mucus. Infective exacerbations are a major determinant of morbidity and mortality in CF patients. These infections are clinically challenging, and antimicrobial treatment should effectively target the organisms and be delivered early to improve survival. Ceftobiprole is a fifth-generation cephalosporin antibiotic that is not indicated for the treatment of CF. However, due to its activity against common causes of infective exacerbations in CF such as Staphylococcus aureus, including MRSA, and Pseudomonas aeruginosa where resistance has not developed, it has utility for managing infective exacerbations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To describe the use of ceftobiprole in the treatment of infective exacerbations in CF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>Ten patients with CF (age 24\u201363; six male and four female) were treated with ceftobiprole for infective exacerbations following discussion within the multi-disciplinary team. In most patients, ceftobiprole was given concomitantly with other antibiotics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All patients had positive sputum cultures for S. aureus (including nine MRSA), and seven patients had concomitant P. aeruginosa infection. Ceftobiprole treatment was associated with improved lung function, and markers of systemic inflammation decreased for most patients, with some variation. There was good tolerability in all but four patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Ceftobiprole presents a therapeutic option for susceptible infections in CF patients with limited treatment options. Its broad-spectrum coverage may help to reduce polypharmacy. However, further clinical studies are needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jacamr\/dlaf077","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T09:33:36Z","timestamp":1747647216000},"source":"Crossref","is-referenced-by-count":0,"title":["Ceftobiprole in cystic fibrosis: a case series"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9146-2873","authenticated-orcid":false,"given":"Lisa","family":"Nwankwo","sequence":"first","affiliation":[{"name":"Pharmacy Department, Royal Brompton and Harefield Hospital, Guy\u2019s and St. Thomas\u2019 NHS Foundation Trust , London SW3 6NP ,","place":["UK"]},{"name":"MRC Centre for Molecular Bacteriology and Infection, Imperial College London , 5.40 Flowers Building Armstrong Road, London SW7 2AZ ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Schelenz","sequence":"additional","affiliation":[{"name":"Microbiology Department, Kings College Hospital , London SE5 9RS ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Newara","family":"Ramadan","sequence":"additional","affiliation":[{"name":"Microbiology Department, Royal Brompton and Harefield Hospital, Guy\u2019s and St. Thomas\u2019 NHS Foundation Trust , London SW3 6NP ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"2025053006322245700_dlaf077-B1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12967-017-1193-9","article-title":"Cystic fibrosis: current therapeutic targets and future approaches","volume":"15","author":"Rafeeq","year":"2017","journal-title":"J Transl Med"},{"key":"2025053006322245700_dlaf077-B2","doi-asserted-by":"publisher","first-page":"244","DOI":"10.2298\/SARH1204244R","article-title":"Cystic fibrosis","volume":"140","author":"Radlovic","year":"2012","journal-title":"Srp Arh Celok Lek"},{"key":"2025053006322245700_dlaf077-B3","doi-asserted-by":"publisher","first-page":"CD009529","DOI":"10.1002\/14651858.CD009529.pub4","article-title":"Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation","volume":"4","author":"Lord","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"2025053006322245700_dlaf077-B4","doi-asserted-by":"publisher","first-page":"e1005258","DOI":"10.1371\/journal.ppat.1005258","article-title":"Cystic fibrosis lung infections: polymicrobial, complex, and hard to treat","volume":"11","author":"Filkins","year":"2015","journal-title":"PLoS Pathog"},{"key":"2025053006322245700_dlaf077-B5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.4997\/JRCPE.2013.212","article-title":"Cystic fibrosis","volume":"43","author":"Leitch","year":"2013","journal-title":"J R Coll Physicians Edinb"},{"key":"2025053006322245700_dlaf077-B6","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1093\/jac\/dkq245","article-title":"Newer antibacterial agents and their potential role in cystic fibrosis pulmonary exacerbation management","volume":"65","author":"Parkins","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2025053006322245700_dlaf077-B7","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1177\/1060028014567526","article-title":"Antibiotic management of methicillin-resistant Staphylococcus aureus \u2013associated acute pulmonary exacerbations in cystic fibrosis","volume":"49","author":"Fusco","year":"2015","journal-title":"Annals of Pharmacotherapy"},{"key":"2025053006322245700_dlaf077-B8"},{"key":"2025053006322245700_dlaf077-B9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.pupt.2018.04.007","article-title":"Intravenous fosfomycin for pulmonary exacerbation of cystic fibrosis: real life experience of a large adult CF centre","volume":"50","author":"Spoletini","year":"2018","journal-title":"Pulm Pharmacol Ther"},{"key":"2025053006322245700_dlaf077-B10","doi-asserted-by":"publisher","first-page":"e1004225","DOI":"10.1371\/journal.ppat.1004225","article-title":"Cycling empirical antibiotic therapy in hospitals: meta-analysis and models","volume":"10","author":"Abel zur Wiesch","year":"2014","journal-title":"PLoS Pathog"},{"author":"ADVANZ PHARMA","key":"2025053006322245700_dlaf077-B11"},{"key":"2025053006322245700_dlaf077-B12","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1080\/14787210.2019.1667229","article-title":"Ceftobiprole: drug evaluation and place in therapy","volume":"17","author":"Giacobbe","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2025053006322245700_dlaf077-B13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2025053006322245700_dlaf077-B14","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ijantimicag.2011.11.005","article-title":"A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation","volume":"39","author":"Nicholson","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"2025053006322245700_dlaf077-B15","doi-asserted-by":"publisher","first-page":"e0171229","DOI":"10.1371\/journal.pone.0171229","article-title":"Clinical utility of C-reactive protein to predict treatment response during cystic fibrosis pulmonary exacerbations","volume":"12","author":"Sharma","year":"2017","journal-title":"PLoS One"},{"key":"2025053006322245700_dlaf077-B16","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jcf.2016.10.009","article-title":"Biomarkers for cystic fibrosis drug development","volume":"15","author":"Muhlebach","year":"2016","journal-title":"J Cyst Fibros"},{"key":"2025053006322245700_dlaf077-B17","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/1471-2466-14-150","article-title":"Role of C-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis","volume":"14","author":"Gir\u00f3n-Moreno","year":"2014","journal-title":"BMC Pulm Med"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/3\/dlaf077\/63227765\/dlaf077.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/7\/3\/dlaf077\/63227765\/dlaf077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T10:32:29Z","timestamp":1748601149000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlaf077\/8136467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4,29]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlaf077","relation":{},"ISSN":["2632-1823"],"issn-type":[{"type":"electronic","value":"2632-1823"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,4,29]]},"article-number":"dlaf077"}}